Phase 1 Open-Label Two-Way Cross Over Study to Assess the Pharmacokinetic Profile of Two Formulations of PB1023 Injection Following a Single Dose Administered By Subcutaneous Injection in Adult Subjects With Type 2 Diabetes Mellitus (T2DM).

Trial Profile

Phase 1 Open-Label Two-Way Cross Over Study to Assess the Pharmacokinetic Profile of Two Formulations of PB1023 Injection Following a Single Dose Administered By Subcutaneous Injection in Adult Subjects With Type 2 Diabetes Mellitus (T2DM).

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2012

At a glance

  • Drugs PB 1023 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Planned end date changed from 1 May 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top